Ultragenyx agrees to sell rare pediatric disease priority review voucher for $210 million

Ultragenyx Pharmaceutical Inc. entered into an asset purchase agreement on October 6, 2026 to sell a Rare Pediatric Disease Priority Review Voucher to an unnamed buyer, according to a Form 8-K filed with the SEC. The agreement, referred to as the PRV Asset Purchase Agreement, covers the sale of the voucher to the buyer.¹

The voucher traces back to an FDA approval. Ultragenyx received the PRV from the FDA on August 19, 2026 after the agency approved its gene therapy for adult and pediatric patients eight years and older with glycogen storage disease type Ia, marketed as GENGLYCOS and known by the generic name pariglasgene brecaparvovec-opnr, also referred to by its development code DTX401.¹

Under the deal terms, the buyer agreed to pay Ultragenyx $210 million in cash when the transaction closes.¹ A portion of that sum carries an existing obligation: under a patent license agreement with the U.S. Department of Health dated December 10, 2018, Ultragenyx must pay 20% of the gross proceeds from the voucher sale to the NIH after closing.¹

The filing notes standard deal protections and a pending regulatory step. The agreement contains customary representations, warranties, covenants, and indemnification provisions subject to certain limitations, and closing remains conditioned on clearing antitrust review under the Hart-Scott-Rodino Act, including expiration or earlier termination of the required waiting period.¹

Ultragenyx said the full agreement text will accompany a future annual filing rather than this report, with the summary in the 8-K serving only as an overview of its terms. The 8-K was signed October 7, 2026 by Howard Horn, the company's Executive Vice President and Chief Financial Officer, Corporate Strategy.